Study Evaluating the Safety and Feasibility of Platelet-rich Plasma to Treat Facetogenic Low Back Pain

NCT ID: NCT05250947

Last Updated: 2024-07-17

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 4 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-01-05
• Study Completion Date: 2024-05-20

Brief Summary

This study is being done to assess the safety of using the Angel Concentrated Platelet Rich Plasma System to process Platelet Rich Plasma (PRP) to treat arthritis of the low back (lumbar spondylosis).

Detailed Description

This study is a pilot of the safety of using the FDA cleared Angel® Concentrated Platelet Rich Plasma System and Angel® cPRP Processing Set to process PRP to treat arthritis of the low back (lumbar spondylosis). Subjects will be screened at outpatient clinic visit appointments and interested qualified subjects will be consented and offered participation in this trial. Once consent has been obtained baseline values will be established and subjects will begin treatment and follow-up for the next 12 months. A final visit for evaluation and collection of lab samples will be conducted at the end of the study.

Conditions

Lumbar Spondylosis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

PRP Injection Arm

The FDA cleared Angel® Concentrated Platelet Rich Plasma System and Angel® cPRP Processing Set will be used to process the PRP. The targeted final PRP volume of 6 ml will be injected in up to 4 facet joints (2 levels) at 1.5 ml per joint.

Group Type: EXPERIMENTAL

Angel® Concentrated Platelet Rich Plasma System

Intervention Type: DEVICE

Angel® Concentrated Platelet Rich Plasma System and Angel® cPRP Processing Set will be used to process the PRP.

Platelet Rich Plasma

Intervention Type: DRUG

6 ml will be injected in up to 4 facet joints (2 levels) at 1.5 ml per joint

Interventions

Angel® Concentrated Platelet Rich Plasma System

Angel® Concentrated Platelet Rich Plasma System and Angel® cPRP Processing Set will be used to process the PRP.

Intervention Type: DEVICE

Platelet Rich Plasma

6 ml will be injected in up to 4 facet joints (2 levels) at 1.5 ml per joint

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Clinical and radiographic (MRI, CT or lumbar x-ray) evidence of symptomatic facet arthropathy involving the bilateral bottom two facets (e.g., L4-5 or L5-6 and L5-S1 or L6-S1).
• Positive response, defined according to current clinical standards for the diagnosis of facet-mediated low back pain as greater than or equal to 75% pain improvement (as reported by patient) to diagnostic medial branch nerve blocks, one block with lidocaine and the other with bupivacaine.
• Low back pain VAS score of greater than or equal to 5 at the clinical visit just prior to the first medial branch nerve block.

Exclusion Criteria

• Prior facet related procedure (intraarticular corticosteroid injection, radiofrequency ablation (RFA)) in last 6 months or prior fusion in the bottom two facets.
• Current opioid use of greater than 50mg oral morphine milligram equivalents per day.
• No advanced imaging (MRI, CT or lumbar x-ray) of the lumbar spine within the last 6 months.
• BMI > 34.99 (WHO class I obesity).
• Active systemic or local infection as evidenced by fever >100.4 degrees Fahrenheit, or any other clinical signs or symptoms of infection within 24 hours of the procedure.
• On anticoagulation drug and has been on hold for less than 7 days prior to the investigational procedure.
• Imaging evidence of high likelihood of failure for intra-articular injection in the opinion of the PI or delegate review of MRI, CT or lumbar x-ray imaging.
• History of chronic thrombocytopenia (or pre-operative platelet count less than 195,000 per μl).
• Undergoing chemotherapy at time of injection.
• Pregnant or breastfeeding.
• Use of illicit drugs within 30 days prior to study entry.
• NSAID use during the pre-procedural period (one week before Treatment Day 0).
• Preoperative hematocrit less than 36%.
• History of hemodynamic instability or inability to maintain stable oncotic pressure.
• History of prolonged clotting times.
• Prior history of lumbar procedure.
• Redness, swelling, rash or other concerning lesions at the injection site just prior to the procedure.
• Prior history of allergy to lidocaine or other local anesthetic agent.

• Minimum Eligible Age: 22 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Matthew Pingree

OTHER

Sponsor Role: lead

Responsible Party

Matthew Pingree

Principal Investigator

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Matthew Pingree, MD

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic

Locations

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Countries

United States

Other Identifiers

18-011475

Identifier Type: -

Identifier Source: org_study_id